Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 17, 2026

Bond Traders See Tipping Point Toward New Era of Higher Yields

View original at finance.yahoo.com
Bond Traders See Tipping Point Toward New Era of Higher Yields (Bloomberg) -- A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Traders now see a Federal Reserve interest-rate hike as a lock by March, a dramatic reversal from late February 2026 when two quarter-point cuts were expected for the year.

    60% confidence
  • Price action is concerning for two reasons: long-end rates are rising globally which tend to feed on each other, and the prospect of Fed hikes is coming into the market narrative.

    60% confidence
  • Higher yields on long-term Treasuries, a benchmark for mortgage rates and corporate loans, are likely to reignite talk of growth risks from elevated oil prices.

    60% confidence
  • The Iran war has flipped the bond-market narrative on its head since late February, when two quarter-point cuts were expected for 2026.

    60% confidence
  • The interest rate range has moved higher and will remain elevated unless the Strait of Hormuz is opened.

    60% confidence
  • The primary worry is that expectations for hotter inflation are taking hold, which adds pressure on incoming Fed Chair Kevin Warsh and spoils bets that he will deliver rate cuts soon after taking the helm.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com